Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended-release niacin/laropiprant in cardiovascular disease and low HDL-C
NCT01308203Phase 4Terminated
- Start
- Oct 2011
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of laropiprant + niacin in dyslipidemia. Started Oct 2011; status: terminated.
02
Drugs
laropiprant + niacin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT01308203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01308203.